Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioAge Labs, Inc. (BIOA)

BioAge Labs doses first patient in Phase 2 DME trial of oral BGE-102

Neutral Impact 3 of 5 product/contract Written later

BioAge Labs said the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial of once-daily oral BGE-102 in adults with diabetic macular edema. The filing also updated the trial design, with topline results expected in the second half of 2027, which is a clinical milestone rather than a financial result for shareholders.

Key points

  • First participant dosed in QUELL-DME, a Phase 2 trial of oral BGE-102, an NLRP3 inhibitor
  • Trial plans about 180 participants randomized 1:1:1 across three arms over 12 weeks of dosing, with a four-week follow-up
  • Primary endpoint is change in best-corrected visual acuity at week 12
  • Topline results expected in the second half of 2027

The filing

CompanyBioAge Labs, Inc. (BIOA)
Form8-K, current report
Filed with the SECOct 2, 2026, 4:15 PM ET
Accession number0001193125-26-412300

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.